KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms
暂无分享,去创建一个
Kai-Cheng Hsu | Jinn-Moon Yang | Jhang-Wei Huang | Chih-Ta Lin | Yi-Yuan Chiu | Jen-Hu Tseng | Syuan-Ren You | Jinn-Moon Yang | Y. Chiu | Jhang-Wei Huang | Jen-Hu Tseng | Chih-Ta Lin | K. Hsu | Syuan-Ren You
[1] G. Hong,et al. Nucleic Acids Research , 2015, Nucleic Acids Research.
[2] Susan O'Brien,et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[4] Michele Magrane,et al. UniProt Knowledgebase: a hub of integrated protein data , 2011, Database J. Biol. Databases Curation.
[5] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[6] Susumu Goto,et al. KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..
[7] Frances M. G. Pearl,et al. MoKCa database—mutations of kinases in cancer , 2008, Nucleic Acids Res..
[8] M. Kimmel,et al. Conflict of interest statement. None declared. , 2010 .
[9] Norbert Haider,et al. Functionality Pattern Matching as an Efficient Complementary Structure/Reaction Search Tool: an Open-Source Approach , 2010, Molecules.
[10] S. Hubbard. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.
[11] Richard A Norman,et al. Structural approaches to obtain kinase selectivity. , 2012, Trends in pharmacological sciences.
[12] Chih-Chieh Chen,et al. (PS)2: protein structure prediction server , 2006, Nucleic Acids Res..
[13] K. Shokat,et al. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. , 2011, Annual review of biochemistry.
[14] E. Canaani,et al. Chronic myelogenous leukemia: biology and therapy. , 1993, Leukemia.
[15] Chih-Chieh Chen,et al. (PS)2-v2: template-based protein structure prediction server , 2009, BMC Bioinformatics.
[16] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[17] P. Furet,et al. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.
[18] Alan F. Scott,et al. McKusick's Online Mendelian Inheritance in Man (OMIM®) , 2008, Nucleic Acids Res..
[19] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[20] References , 1971 .
[21] P E Bourne,et al. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. , 1998, Protein engineering.
[22] E. Birney,et al. Pfam: the protein families database , 2013, Nucleic Acids Res..
[23] Hilmar Weinmann Dr. and,et al. Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .
[24] P Reichardt,et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Paul Reichert,et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. , 2009, Biochemistry.
[26] Wei-Sheng Huang,et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.
[27] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[28] J. Radich,et al. Measuring response to BCR‐ABL inhibitors in chronic myeloid leukemia , 2012, Cancer.
[29] David S. Goodsell,et al. The RCSB Protein Data Bank: redesigned web site and web services , 2010, Nucleic Acids Res..
[30] Kai-Cheng Hsu,et al. SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties , 2010, Nucleic Acids Res..
[31] Tim J. P. Hubbard,et al. SCOP database in 2004: refinements integrate structure and sequence family data , 2004, Nucleic Acids Res..
[32] Hilmar Weinmann,et al. Drug discovery process for kinase inhibitors. , 2005, Chembiochem : a European journal of chemical biology.
[33] Robert D. Finn,et al. InterPro: the integrative protein signature database , 2008, Nucleic Acids Res..
[34] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[35] Angel Herráez,et al. Biomolecules in the computer: Jmol to the rescue , 2006, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.
[36] Chun-Yu Lin,et al. PPISearch: a web server for searching homologous protein–protein interactions across multiple species , 2009, Nucleic Acids Res..
[37] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[38] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[39] Jonathan D Cooper,et al. p38α stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis , 2004, Molecular and Cellular Neuroscience.
[40] R. Venkataraghavan,et al. Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..
[41] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[42] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[43] S. Clifton,et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. , 1995, Genomics.
[44] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[45] Kai-Cheng Hsu,et al. Core Site-Moiety Maps Reveal Inhibitors and Binding Mechanisms of Orthologous Proteins by Screening Compound Libraries , 2012, PloS one.
[46] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[47] L. Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.
[48] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[49] Hilmar Weinmann,et al. Editorial: Drug Discovery Process for Kinease Inhibitors , 2005 .
[50] Jeffrey Jie-Lou Liao,et al. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.
[51] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[52] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[53] Malcolm J. McGregor,et al. A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors , 2007, J. Chem. Inf. Model..
[54] James D. Griffin,et al. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. , 2010, Blood.
[55] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[56] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[57] Todd J. A. Ewing,et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..
[58] Jinn-Moon Yang,et al. GEMDOCK: A generic evolutionary method for molecular docking , 2004, Proteins.
[59] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.